Attachment
In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics. In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.
At $47.7bn, cancer is one of the largest and fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.
This report provides coverage of over 95% of the total market for cancer products and enables the reader to understand the issues behind the market-leading products of today and forecasts the market-leading products of tomorrow. The report allows the reader to understand which pharmaceutical companies will be the dominant forces in the cancer arena, and which products will be the strongest performers over the period 2009-14.
Business Insights: Cancer Market Outlook to 2014:
http://www.reports-
Business Insights: More market data and market reports:
http://www.reports-
